Fujikyu Corporation (9966)

Overview

Alphamab Oncology is a prominent biopharmaceutical company based in Suzhou, People's Republic of China, founded in 2008. Specializing in cancer treatment, the company is dedicated to the research, development, manufacture, and commercialization of biotherapeutics. Its operations span across multiple stages of drug development, from clinical trials to the commercialization of treatments for a variety of cancers. Alphamab Oncology's innovative approach focuses on addressing the needs of cancer patients through the deployment of advanced therapeutic solutions and biotherapeutics.

Products and Services

KN035 (ENWEIDA): An injectable PD-L1 inhibitor designed for adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors.

KN026: A Phase III clinical trial anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antibody (BsAb) intended for treating HER2-positive breast cancer and HER2-positive gastric cancer or gastroesophageal junction cancer.

KN046: A bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor currently in Phase III clinical trials. It aims to treat various cancers including non-small cell lung cancer (NSCLC), squamous NSCLC, triple-negative breast cancer, and recurrent and metastatic esophageal squamous cell carcinoma.

JSKN003: A biparatopic HER2-targeting antibody-drug conjugate (ADC) in Phase III trials for HER2-expressing advanced or metastatic solid tumors, HER2-low expression breast cancer, platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer.

JSKN016: A Phase II clinical trial bispecific ADC targeted at advanced malignant solid tumors, lung cancer, and breast cancer.

KN019: An immunosuppressive agent under Phase II clinical trial for prevention of organ rejection in adult patients receiving a kidney transplant.

JSKN033: A subcutaneous ADC in Phase I clinical trial, aimed at treating HER2-expressing advanced or metastatic solid tumors.

Pre-Clinical Stage Products: Alphamab Oncology is also developing a range of products targeting oncology applications at the pre-clinical stage, including JSKN022, JSKN027, JSKN021, JSKN020, and JSKN028, which are geared towards various oncology applications.